Ketanserin's sympatholytic and serotonin2-receptor blocking actions precede the hypotensive effects.
The hypotensive action of ketanserin in humans remains incompletely defined but may be mediated by factors unrelated to vascular alpha 1 or serotonin2-receptor blockade. We examined the effects of ketanserin on indices of sympathetic drive, alpha 1- and serotonin2-receptor responses, and sympathetic tone in 13 elderly men with mild hypertension. Studies were performed after ten days and six weeks of double-blind assignment to placebo and ketanserin 40 mg twice daily. An eight week long single-blind, placebo washout period separated the double-blind phases. In the entire group, ketanserin lowered BP and heart rate significantly after six weeks but not at ten days. In contrast, plasma noradrenaline, an index of sympathetic drive, and platelet aggregation in response to 1 microM serotonin, an index of serotonin2-receptor antagonism, declined significantly after both ten days and six weeks (P < 0.05) on ketanserin versus placebo. Mean BP after six weeks on ketanserin fell to > 10% in seven patients (responders) and to < 10% in six subjects (nonresponders). Responders had higher baseline SBPs and heart rates compared with nonresponders. Even in responders, BP was reduced at six weeks but not after ten days on ketanserin versus placebo. Plasma and platelet noradrenaline, plasma renin activity, and platelet responses to serotonin at baseline and during ketanserin did not distinguish between responders and nonresponders. Ketanserin reduces sympathetic drive and antagonizes serotonin2-receptors in the short term. The relationship of these actions to the hypotensive effect of ketanserin, which is delayed and dependent on the initial BP, is unclear.
Egan
B M
BM
Department of Pharmacology, Medical University of South Carolina, Charleston 29425.
Stepniakowski
K
K
Zweifler
A J
AJ
D004311:Double-Blind Method; D006801:Humans; D007022:Hypotension / Q000188:drug therapy*; D007650:Ketanserin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010919:Placebos; D012702:Serotonin Antagonists / Q000627:therapeutic use*; D013565:Sympatholytics / Q000627:therapeutic use*; D013997:Time Factors
D010919:Placebos; D012702:Serotonin Antagonists; D013565:Sympatholytics; D007650:Ketanserin